Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alendronate + dibotermin alfa
- Development stage
- Phase 2
- Lead developer
- University of Baghdad
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Hydrogel Systems → Drug Delivery Systems
- Administration
- Topical
01
Overview
Mixed Gel is an investigational topical combination formulation developed by the University of Baghdad for use in dental implantology. It consists of alendronate sodium, a nitrogen-containing bisphosphonate that inhibits osteoclast-mediated bone resorption by targeting farnesyl pyrophosphate synthase, and recombinant human bone morphogenetic protein-2 (rhBMP-2, also known as dibotermin alfa), an osteoinductive cytokine that stimulates the differentiation of mesenchymal stem cells into osteoblasts. The gel is applied locally to the osteotomy site during dental implant placement in patients with partial edentulism to enhance primary and secondary implant stability and minimize crestal bone loss. The formulation was evaluated in a randomized controlled clinical trial (NCT04140006).
- Other names
- Mixed GelAlendronate Sodium In-situ Gel and Recombinant Human Bone Morphogenic Protein 2ALN/rhBMP-2 gel
02
Targets
ACVR1 (Activin receptor type I)ACVR2A (Activin receptor type 2A)ACVR2B (Activin receptor type IIB)BMPR1ABMPR1BBMPR2 (Bone morphogenetic protein receptor type II)FDPS (Farnesyl pyrophosphate synthase)GGPPS1 (Geranylgeranyl pyrophosphate synthase)BMPR (Bone morphogenetic protein receptor)
Beyond the preview
Go deeper on alendronate + dibotermin alfa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alendronate + dibotermin alfa.